Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gammaplex (Intravenous immunoglobulin) Clear all
Completed Phase 3 Interventional Results available

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098
View directory record Official record
Conditions
Thrombocytopenia, Neonatal Alloimmune
Interventions
Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Withdrawn Phase 3 Interventional

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

NCT03749096
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Intravenous Immunoglobulins, Human, Placebos
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 5, 2026, 3:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190
View directory record Official record
Conditions
Multifocal Motor Neuropathy (MMN), MMN
Interventions
Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT05363358
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

NCT00473824
View directory record Official record
Conditions
Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions
Hepatitis C Immune Globulin Intravenous (Human) 5%
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Not listed Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925
View directory record Official record
Conditions
Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
Interventions
Gammaplex 5%
Drug
Lead sponsor
Isaac Melamed
Industry
Eligibility
4 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 1Phase 2 Interventional

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

NCT00642655
View directory record Official record
Conditions
Kidney Transplant
Interventions
IVIG and Rituximab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

NCT00299988
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Intravenous Immunoglobulin, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults

NCT05269082
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02604810
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IGIV-C 10%, IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

NCT00115778
View directory record Official record
Conditions
Hypogammaglobulinemia, Lung Transplantation
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 2 Interventional Results available

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

NCT01556347
View directory record Official record
Conditions
Heart Transplantation
Interventions
Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 67 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Gammaglobulin for Sickle Cell Pain Crises

NCT01757418
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Immune Globulin Intravenous (IVIG), Normal saline
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
6 Years to 13 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

NCT03630211
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145
View directory record Official record
Conditions
Immunoproliferative Disorder
Interventions
Bacteriophage, rhuCD40L, KLH
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 3:36 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for GAMMAGARD in Primary Immunodeficiency

NCT02123615
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

NCT02100969
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
HIZENTRA ®
Drug
Lead sponsor
Mazen Dimachkie, MD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Kansas City, Kansas • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 3:36 PM EDT